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Abstract
The introduction of living donor liver transplantation (LDLT) has been one of the most remarkable steps in the field of liver
transplantation (LT). First introduced for children in 1989, its adoption for adults has followed only 10 years later. As the
demand for LT continues to increase, LDLT provides life-saving therapy for many patients who would otherwise die
awaiting a cadaveric organ. In recent years, LDLT has been shown to be a clinically safe addition to deceased donor liver
transplantation (DDLT) and has been able to significantly extend the scarce donor pool. As long as the donor shortage
continues to increase, LDLT will play an important role in the future of LT.
Introduction and historical notes
Today, liver transplantation (LT) represents the
treatment of choice for end-stage liver disease and
represents the culmination of a long history of
innovations made by liver surgeons based on hemor-
rhage control, appreciating the occurrence of regen-
eration and understanding the liver anatomy [1].
Resective and transplant liver surgery influenced
each other reciprocally during their historical evolu-
tion. On one hand, advances in liver transplantation
surgery were based on the evolution of the surgical
technique of liver resection. On the other hand,
innovative concepts in oncologic liver surgery were
developed in the light of new technical features used
for liver transplantation.
Due to improved immunosuppressive regimens,
tissue preservation, reduction of infectious disease,
and better postoperative management, orthotopic LT
has achieved patient and allograft survival rates that
have expanded both the indications for transplanta-
tion and the number of potential recipients awaiting
liver transplantation [2].
Despite supportive legislation, media network sys-
tems and attempts to raise public awareness, the
actual donor numbers have remained relatively con-
stant and do not meet the growing need for more
organs (Figure 1). In 2004, for example, 2035
patients were listed for liver replacement, but only
1262 deceased donor livers became available in
the Eurotransplant organization. At present, the
combined mortality report for pediatric and adult
patients on the waiting list ranges between 10% and
30% [3].
The disparity between organ demand and the
cadaveric donor supply for children resulted initially
in a pre-transplant mortality around 25% and was
disproportionately high compared with adult
patients [4]. The problem of size mismatch and the
different epidemiology of pediatric donorship and
terminally diseased children were responsible for
that situation [5]. This stimulated the development
of technical innovations, based on the segmental
anatomy of the liver, which facilitated transplanting
parts of large deceased donor livers into smaller
recipients.
The first step in solving the size mismatch problem
was the introduction of reduced-size liver transplanta-
tion (RSLT). The technique was originally described
by Bismuth and Houssin [6] and consisted of
performing a resection of the graft on the back table
to reduce it to a size that fitted the small pediatric
recipients [6/8]. This procedure was validated in the
late 1980s [7,8] and later became standard practice
worldwide, with 1-year survival rates of around 80%
[7/9]. Although RSLT decreased the waiting list
mortality of nearly 50% among children, it increased
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the number of adult patients on the waiting list, since
the organs were withdrawn from the adult organ pool
[10,11].
This problem was addressed by split liver trans-
plantation (SLT), in which a deceased donor liver is
divided into two parts for two recipients. The
technique was first described by Pichlmayr in 1988
[12,13]. It allowed the preparation of two split grafts
by dividing all vascular and biliary structures and
parenchyma for the benefit of two recipients, one
receiving a right lobe graft and the other receiving a
left lobe (segments 2/4) or left lateral one (segments
2/3).
The first series of SLT was reported by Broelsch
and co-workers at the University of Chicago [14], and
in the early 1990s, the technique was definitely
validated by other groups [10,11,15].
The results turned out not to be as expected, but
revealed the ‘Achilles’ heel’ of the procedure: the
cut edge of segment 4 and the biliary system. Hence,
in the presence of a poorly functioning graft, both
recipients were in jeopardy and the re-transplantation
rate increased [16]. The bottom line was no real
increase in donor organ availability for both pediatric
and adult recipients. In addition, for the adults, a
new phenomenon was discovered: the small for
size graft syndrome, which prevented expansion of
the procedure of hemiliver transplant between two
adults [17].
The big hope for SLT temporarily vanished until
the increasing pressure on transplant surgeons
prompted them to change the extracorporeal split
procedures of preserved organs into harvesting the
donor organs in situ or by sophisticated ex situ
procedures, avoiding the likelihood of a non-viable
transplant. The hazards and the risks of a split harvest
induced a drastic reduction of the split procedure to
B/20% of all donors. In addition, the logistics of
sharing were another hampering factor in its broader
application. Currently, most centers perform SLT
under their own responsibility and within their own
region to avoid long distance shipping and extended
cold ischemia time. Unfortunately, the wider applica-
tion of the split technique is still hindered by the
lack of experience and unwillingness of some centers
to split every suitable donor liver, making this
procedure account for B/20% of all LT performed
[18,19].
Notwithstanding, SLT partially increased the donor
pool and had an important impact on the waiting list
and on the outcome of pediatric liver transplantation
[20/24].
Facing the downsides of the RSLT and SLT series
and the growing need for liver grafts, the development
of segmental LT from a living donor was a natural
consequence. In 1989, Raia et al. reported the first
two transplantations using grafts taken from living
donors, but both recipients died of medical complica-
tions [25]. The first successful living donor liver
transplantation (LDLT) from a mother to her son
was reported by Strong et al. with a graft survival of
14 months and no donor morbidity [26]. Simulta-
neously, Broelsch et al.’s group in Chicago established
a living related liver program in a systematic fashion
and they were able to demonstrate that survival of
LDLT was comparable to that of deceased donor liver
transplantation (DDLT) [17]. Equivalent results were
obtained by the group of Tanaka et al. in Kyoto soon
afterward, proving the clinical effectiveness of LDLT
in children [27]. The procedure was gradually
adopted more widely, especially in Asian countries,
where cadaveric donors were scarce. In 1994,
Yamaoka et al. first reported the use of a right lobe
for transplantation, and Marcos et al. demonstrated in
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Figure 1. Progressive increase of the disparity between organ offer and demand in Europe (data from ELTR-Report 2004).
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their series of 30 patients that right lobe LDLT can be
performed with minimal risk to the donor and
recipient [28,29]. Up to now, almost 3500 adult-to-
child and 2500 adult-to-adult LDLTs have been
performed worldwide (Figure 2).
LDLT emerged as the only innovation to signifi-
cantly expand the scarce donor pool in countries in
which the growing demands of organs are not met by
the shortage of available cadaveric grafts.
The application of LDLT is associated with several
theoretical advantages: (1) the transplantation can be
performed on an elective basis before serious decom-
pensation of the recipient; (2) grafts are in excellent
condition and complications due to preservation
injury are absent; and (3) the possibility of LT for
recipients who might otherwise not be eligible for
standard DDLT still exists. The drawback of this
procedure is represented by the potential risk of death
or serious complications to the donor and a series of
still unsolved technical, physiological, and ethical
questions.
The donor
Donor’s evaluation
LDLT is based on two main principles: (1) donor
morbidity and mortality must be kept to a minimum;
and (2) graft and recipient survival should be as high
as in full size DDLT.
In this regard, careful evaluation and selection of
the donor minimizes the risk to the donor and
maximizes the benefit to the recipient [30/32].
All potential donors therefore undergo a strict
multi-step evaluation protocol, which normally in-
cludes exhaustive medical and psychological evalua-
tions of the donor, as well as a precise anatomical
study of the liver [33,34]. The published donor
evaluation protocols are very similar [27,28,35]. Our
multi-step evaluation protocol is reported in Table I
[36,37].
The donors are generally, genetically or strongly
emotionally, related to the recipient. Exclusion cri-
teria for donors are: age under 18 years, obesity
(BMI/30 mg/m2), and significant medical co-mor-
bidities [37].
The study of vascular and biliary anatomy of the
liver can be performed in different ways (e.g. angio-
graphy, angio-CT, magnet resonance imaging,
etc.). Based on our own experience, we prefer the
‘all-in-one’ CT procedure [38/40]. Data obtained by
an all-in-one CT scan are further analyzed with
HepaVision software (MeVis, Bremen, Germany)
for a 3-D reconstruction of vascular functional liver
anatomy (Figure 3). This new technology offers the
following advantages: (1) 3-D reconstruction of the
vascular and biliary anatomy; (2) automatic calcula-
tion of the liver volumetry, as well as the territorial
volumes; (3) 3-D display of the individual territorial
liver mapping; (4) risk analysis of the hepatic vein
dominance relationship; and (5) virtual simulation of
the liver partition [41,42].
The study of liver volume, generally performed by
means of CT, represents another key point of the
evaluation protocol of the donor. It must be accurate,
as much as possible, in order to not only guarantee
enough graft volume to the recipient but mainly to
assure enough residual liver volume to the donor. In
general, a graft volume body weight ratio (GVBWR)
of 0.8 [43] or 40% of the recipient’s standard liver
volume [32,44] is recommended as a minimum cut-
off for the recipient, even though successful trans-
plantations have been reported with GVBWR B/0.7
[45,46]. The Kyoto group showed a statistically
significant correlation between complication, graft
loss, and a GVBWR of B/0.8 [47]. Similarly, the ratio
between residual liver volume and the donor’s weight
should also be no less than 0.8.
The role of liver biopsy (LB) in donor selection
remains controversial, since the procedure is asso-
ciated with additional potential risks for the donor.
We believe that LB in donor selection for right adult
LDLT is mandatory, once the initial donor screening
and non-invasive evaluation is complete [36].
During the psychological evaluation, donors are
assessed for altruism and possible coercion [48]. In
our protocol, in the case of adult LDLT, the psycho-
logical evaluation is held twice, first for the donor
alone and second together with the recipient.
From April 1998 to May 2005, we evaluated 895
potential donors for 433 adult patients and 86
potential donors for 57 pediatric recipients. Almost
85% of evaluated potential donors were excluded. In
the adult group, 773 (86%) donors were rejected,
leaving only 122 suitable donors. For pediatric
patients, 62 of 86 (72%) donors were rejected. In
the adult group, 28% of donors were excluded owing
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Figure 2. LDLTs performed worldwide from 1989 up to 2004 (almost 6000 LDLTs within 15 years).
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to reasons related to the recipient. In 37% of cases in
the pediatric group, the evaluation process of the
donor was stopped, because the recipient underwent a
DDLT. Only 14% of potential donors in our series
were considered suitable candidates for donation, and
all efforts should be made to create more effective
screening evaluation protocols.
Donor’s operation
Nowadays the donor’s left lateral hemihepatectomy
represents a standardized procedure [49]. In addition,
the right hemihepatectomy is almost standardized
worldwide [27,31,33,34,50/53], but some points of
discussion are still open. One major point of debate is
whether the middle hepatic vein (MHV) should be
harvested or not in the case of right or left hemi-
hepatectomy. Based on radiological studies on parti-
tion of the venous vascular anatomy of the liver
[41,42], as well on our own surgical experience
[53,54], we can state that the MHV can be harvested
without causing any outflow decompensation in the
residual liver [53,55/57]. Additionally, by performing
a ‘carving’ resection along the MHV, a volume-
sparing resection could be also performed [54].
It is well known that the division of the right hepatic
duct is one of the most important steps in the donor
hepatectomy, potentially influencing both the out-
Figure 3. Three-dimensional reconstruction of vascular and biliary anatomy of a donor liver by means of MeVis-CT# [43,44].
Table I. Evaluation protocol for potential living liver donors at the University of Essen, Germany [38].
Step 1 Clinical evaluation: history and physical examination
Lab tests: blood group, hematological tests, chemistry, coagulation profile,
C-reactive protein, pregnancy test
Serology: hepatitis A, B, C; HIV, CMV, HSV, EBV
First informed consent
Step 2 Imaging studies: ‘all-in-one’ CT scan
First psychological evaluation
Step 3 Special studies: ECG, chest X-ray, pulmonary function test,
echocardiography, stress test
Laboratory: thyroid function test (TSH, T3, T4), immunoglobulins IgA, IgG, IgM,
iron, transferrin, ferritin, a-1-antitrypsin, ceruloplasmin, tumor markers
(CEA, AFP, CA 19-9), factors V, VII, VIII, protein C and S, APCR, and urine
sediment
First autologous blood donation
Selected consultations
Step 4 Second psychological evaluation (donor and recipient)
Histology: liver biopsy
Hepatologist consultation
Second autologous blood donation
Step 5 Anesthesiological consultation
Ethics board evaluation
Final informed consent
HIV, human immunodeficiency virus; CMV, cytomegalovirus; HSV, herpes simplex virus; EBV, Epstein/Barr virus; CT, computed
tomography, ECG, electrocardiography; TSH, thyroid-stimulating hormone; T3, triiodothyronine, T4, thyroxine; CEA, carcinoembryonic
antigen; AFP, alpha-fetoprotein; APCR, activated protein C resistance.
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come of the anastomosis in the recipient and the
safety of the donor. Therefore, an intraoperative
cholangiogram should be performed whenever the
standard preoperative imaging protocols (i.e. MRI or
CT) do not provide reliable information about the
anatomy of the biliary tree. Based only on the 3-D
pictures provided by the all-in-one CT, we could
avoid an intraoperative cholangiogram in the last 67
cases, and no biliary complication in the donor was
observed.
Additionally, the method and timing of biliary
dissection should be mentioned. Although most
centers perform the bile duct division at the end of
the parenchymal transection, we are convinced that an
early suprahilar bile duct division should be per-
formed before the parenchymal transection [53].
The technique of hepatic duct probing and early
division is safe, preserves the vascular supply of the
hepatic duct, and allows an excellent yield of a single
orifice for the recipient anastomosis. Moreover, it
provides a precise definition of the anatomy of the
hepatic duct confluence and facilitates one of the most
challenging elements of the donor hepatectomy.
Careful preparation and blood-saving surgery will
significantly lower the postoperative morbidity. We
use a cell saver in every instance. The procedure is
performed without hilar occlusion or by using only
intermittent clamping. For the parenchymal transec-
tion, ultrasound or waterjet dissectors can be used in
combination with electrocautery. After removal, the
graft is flushed with either UW or HTK solution,
although no difference between the two solutions has
been reported [58]. We do not use a T-tube for biliary
decompression of the donor’s liver, although this is
carried out in some centers [53].
Donor morbidity and mortality
Morbidity. The most serious ethical concerns in
LDLT focus on the risks to the donor and relate to
the principle of ‘do no harm’. There is an extensive
literature focused on the incidence and type of
complications after living liver donation, although a
clear definition of what should be considered a
‘complication’ is lacking. Donor morbidity has been
reported in numerous reports and ranges from 0% to
67%, with an overall crude complication rate of 31%
[30,53,59/62]. Biliary complications including bile
leaks and strictures were the most frequently reported
morbidities, with a median of approximately 7%.
Wound infections, pneumonia, abscess, small bowel
obstruction, and incisional hernia occurred in 9/19%
of all donors. Umeshita et al. reported 244 post-
operative complications in 228 of 1853 donors, which
amounts to an overall complication rate of 12% [63].
Right hepatectomies were associated with a greater
morbidity risk than left-sided graft operation. As
surgeons have become more familiar with the proce-
dure, donor outcomes have improved significantly.
Mortality. Overall, there have been 12 donor deaths
reported (10 early and 2 late). Seven of them donated
a right graft, three a left graft [50,53,64/68]. Relating
to the approximately 3800 left and 2200 right
hepatectomies worldwide, the overall mortality risk
is estimated to be 0.16% and 0.38%, respectively
[51]. Causes of death in the adult-to-adult donations
were sepsis in three, massive bleeding in one, pul-
monary embolism in one, postoperative liver failure
on the grounds of an unrecognized congenital lipo-
dystrophy in one, and unknown in one patient. In the
adult-to-child donations, causes of death included
pulmonary embolism in one, anesthetic complications
in one and multiple organ failure in one donor. Again,
the right hepatectomy seems to be associated with a
greater risk than the left lateral. Two additional
donors themselves became candidates for liver trans-
plantation, but died 3 and 10 years afterwards
[30,50,51].
The LDLT recipient
Indications
The indications for LDLT are similar to standard LT
in both adult and pediatric patients. Nonetheless,
clinical experiences have shown that the willingness to
donate increases as the clinical condition of the
recipient worsens. Consequently, there is a trend to
extend the indications for LDLT, especially in tumor
patients (i.e. hepatocellular carcinoma (HCC) repre-
sents 10% of primary indications for standard LT and
23% for LDLT), with surprisingly good results.
Recipient’s operation
Timing of the operation. Generally, the recipient’s
operation follows the donor’s operation in a timely
fashion, with the possibility of overlapping in the case
of two teams of experienced transplant surgeons, with
consequent reduction of the cold ischemic time for
the graft. Notwithstanding, the clinical condition of
the recipient and the indication for transplantation
also dictate a change in the sequence of the surgeries.
For example, in patients with advanced HCC, the
exploration of the recipient should precede the
donor’s hepatectomy.
Technical aspects of recipient’s hepatectomy. The retro-
hepatic inferior vena cava (IVC) should always be
preserved and completely mobilized to guarantee an
optimal IVC occlusion in case of complicated outflow
reconstruction. A temporary porto-caval bypass can
be used selectively in the case of patients with severe
portal hypertension and previous abdominal surgery
or a foreseeable long anhepatic period. The indica-
tions for systemic venovenous bypass (VVB) are still
controversial [69]. In the case of planned duct/duct
biliary anastomosis, the dissection of the bile duct
should be extended deeply into the hilar plate [70,71].
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The time of completion of the hepatectomy (re-
moval of the recipient’s own liver) depends on the
availability of the graft and on the clinical and
hemodynamic condition of the recipient.
Benching the graft
The benching of the right graft became more time-
consuming and complicated with better understand-
ing of the physiology of the venous outflow. The
actual state of the art is to maximize the venous
outflow by reconnecting all major veins, draining the
graft in one single large conduit (‘blanket’ technique)
(Figure 4) [54].
Implantation of the graft
Much emphasis should be placed on the hepatic
outflow tract to prevent graft congestion, a key
problem leading to early postoperative graft dysfunc-
tion. In consideration that the rapid regeneration of
the graft could cause kinking, compression, or torsion
of the outflow tracts, a wide cavotomy of subdiaph-
ragmatic IVC joining the triangulation of the three
hepatic veins became mandatory in right LDLT. The
wide cavotomy (triangle-shaped), combined with a
single large venous conduit, can protect the outflow
even in the case of medial graft rotation.
The portal vein is generally anastomized to the
main portal vein of the recipient. In the presence of
multiple branches of the right portal vein, a single
anastomosis using a common patch is preferred.
The graft hepatic artery is anastomosed to
the proper, right or left, hepatic artery. The bile
duct(s) are reconstructed by using a Roux-en-Y
loop or are anastomosed in an end-to-end/end-to-
side fashion with or without insertion of a T-tube
[71,72].
Size mismatching of the graft
In case of marginal GVBWR (B/0.8) and presence of
portal hypertension (/ 20 mmHg), a small for size
syndrome may develop in a short time. It is mainly
caused by a hypertensive high portal flow, graft
congestion, and consequent reduction of arterial
flow, which can lead to enhanced hepatocyte injury
with consequent graft dysfunction up to graft loss. In
this regard, different surgical solutions with different
results have been proposed and can be summarized in
two groups: the outflow and the inflow schools. The
first, mainly represented by our group and the group
from Hong Kong, is mainly oriented in maximizing
the venous outflow by harvesting the MHV and
performing a wide singular venous conduit
[52,54,55]. The other school of thought aims
to reduce the portal flow, indirectly through the
ligature of splenic artery [73], or directly by means
of a meso-caval shunt [64,74] or hemiportocaval
shunt [75].
Figure 4. Historical evolution of reconstruction of venous outflow in right LDLT [56].
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The actual trend is in reality a combination of the
two schools according to individual patient’s require-
ments, mainly based on intraoperative hemodynamic
monitoring of portal and arterial flows and pressures.
While small for size grafts are a major problem in
adult transplantation, large for size grafts occur
predominantly in children and are associated with
a higher incidence of graft loss due to vascular
complications [76,77].
Recipient’s results
Vascular complications
With the introduction of microsurgery, the incidence
of hepatic arterial thrombosis was reduced dramati-
cally. Two cumulative studies reported an incidence
between 3% and 5%, respectively [43,78]. These
results are far better than the 22% reported at the
start of performing pediatric LDLT with the left
lateral segment [79].
Portal vein thrombosis (PVT) is a rare event. The
caliber and the short length of the vessel are the main
reasons for the low incidence of thrombosis. Several
reports have reported no PVT at all in adult LDLT,
and in our program, we experienced only one case
[34,51,80]. However, in left lateral LDLT, the in-
cidence is between 5% and 8%, attributable mainly to
the diameter disparity between the graft and recipient
portal vein. In particular, children with biliary atresia,
after undergoing a Kasai operation, show a narrow
and sclerotic portal trunk [81].
Biliary complications
Biliary reconstruction remains the Achilles’ heel in
LDLT, with a reported complication rate between 6%
and 35% [72,82,83], including leakage, stricture, or
biliomas, eventually leading to graft loss. In B/50%,
a single duct is obtained, and more often, two or more
ducts are present. The small diameters of the
bile ducts make the anastomosis very demanding
and therefore at high risk for more complications.
Initially, a hepatico-jejunostomy was used in LDLT,
but recently, more and more duct-to-duct biliary
reconstructions have been performed. However,
long-term observation is necessary to confirm the
reported advantages of this procedure.
Outcome
Over the past years, it has been shown that LDLT
for children is superior to DDLT in terms of patient
and graft survival [81]. Several centers reported a
1-year graft and patient survival beyond 90%, and a
3-year graft and patient survival of 78 vs 73%,
respectively [84,85]. Furthermore, the pre-transplant
mortality is significantly decreased. In fact, waiting
list mortality reaches only 2% in centers that perform
pediatric LDLT, but it is still 15% in programs that do
not [83].
With a 5-year graft and patient survival between
72% and 97%, adult LDLT shows at least as good
results as DDLT [33,53,86], although the 3-year graft
survival is slightly lower compared with the standard
DDLT (65% vs 68%, respectively). This is probably
related to different indications / specifically, more
viral cirrhosis, more cancers, and more advanced
liver failures in adult-to-adult LDLT. Interest-
ingly, patients with HCC, who otherwise would
not qualify for a DDLT, have benefited from
LDLT. Of 316 LDLTs performed for HCC, patient
survival and disease-free survival at 3 years were
78.7% and 79.1%, when the Milan criteria were
applied [87].
Extended indications
In consideration of actual donor scarcity, the indica-
tions are result-oriented in terms of best overall and
disease-free survival. In this regard, some indications
are considered not standard, or better defined as
extended indications: (1) HCC beyond Milan criteria;
(2) decompensated end-stage liver disease (UNOS
2A); and (3) hepatitis C (HCV) cirrhosis. For these
reasons, these patients are going to be excluded from
the waiting list for DDLT, and the only alternative
that can be offered to them is LDLT.
HCC beyond Milan criteria
Until the start of the 1990s, the results of DDLT were
very poor, as the main indication for LT was advanced
HCC. As a result, HCC became a contraindication
for DDLT until the introduction of the Milan criteria
by Mazzaferro et al. in 1996 [88]: no extrahepatic
metastases, no macroscopic vascular invasion, single
tumor nodule 5/5 cm or 5/3 tumors 5/3 cm. Apply-
ing the Milan criteria, a 4-year survival of 83% and a
disease-free survival at 4 years of 75% was reached
[88]. Similar results were observed for LDLT in
different centers. Unfortunately, the actual preopera-
tive tumor screening and tumor staging are not always
reliable; the consequence is that sometimes patients
are over-staged before LT, with exclusion of a high
number of patients who could benefit from LT.
Additionally, probabilities of dropping out must be
taken into account, because tumor progression during
the waiting time ranges between 40% and 50% at
2 years after diagnosis. To escape the dilemma of
limited organ availability, LDLT is a good alternative,
offering a short waiting time with consequently less
drop out and reduced mortality in the waiting list.
Additionally, more than 50% of patients in the
published series of LDLT for HCC were beyond the
Milan criteria. For these reasons, Yao et al. proposed
expanding the Milan criteria in the case of LDLT:
single nodule 5/6.5 cm or 5/3 nodules 5/4.5 cm.
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The authors reported a 1- and 5-year survival of 90%
and 75%, respectively [89].
Actually, it seems that the number of tumor nodules
represents a less important factor than diameter,
presence of vascular infiltration, and histological
type associated with different grades of malignancy.
Therefore, Lee et al. suggested extending the Milan
criteria in selected cases with a higher number of
tumor nodules, as long as the HCC were small
without macrovascular invasion [90]. Recently, the
size of the tumor has also been under discussion.
Gondolesi et al. recently reported good results with
LDLT for large HCCs [91,92]. Overall, in patients
with HCC/5 cm (n/12), there were no statistically
significant differences in survival or in freedom from
recurrence between recipients of living donor and
cadaveric grafts. LDLT allows timely transplantation
in patients with early or large HCC.
In conclusion, although complicated factors, such
as donor voluntarism and selection criteria, limit the
role of LDLT for HCC, LDLT allows more patients
to undergo early transplantation, which also results in
a better outcome in cases beyond the Milan criteria.
We need to decide rather, whether a patient with
malignant disease should be offered a chance of life
prolongation. Any other oncological treatment for a
large unresectable HCC would experience unrest-
ricted acceptance if providing the same efficiency as
LT [93].
Extended end-stage liver disease
LDLT for patients with decompensated end-stage
liver disease (UNOS 2A, MELD /30) is controver-
sial. Nevertheless, these patients are most in need of a
timely liver transplant. In our series, patient and graft
survival rates were only 43% [94]. Notwithstanding
the high mortality rate, no donors had regrets about
the procedure, and all donors stated that they would
donate again if presented with the same decision.
LDLT represents a timely and effective alternative to
DDLT in the case of decompensated end-stage liver
disease. Nonetheless, the ethical concerns regarding
risks and benefits for both donor and recipient should
be discussed.
HCV cirrhosis
Approximately 170 million people worldwide have
been infected with HCV. By the year 2020, current
estimates suggest that nearly 14 million people will
have cirrhosis due to chronic HCV. HCV-related
disease accounts for more than half of the indications
for LT in most transplant programs. As waiting lists
continue to expand, the time to transplantation is
becoming increasingly prolonged. The current num-
ber of deaths on the waiting list is, at the moment,
higher for patients with the diagnosis of chronic HCV
infection than for other diagnoses. Liver cirrhosis,
secondary to HCV, represents 30/50% of indications
for LT in European and American countries.
Relapse of HCV occurs virologically in 100% of LT
recipients. Histological recurrence occurs in approxi-
mately 50% of recipients, with ensuing graft failure in
10% of patients by the fifth postoperative year.
Additionally, 8/31% of patients with post transplant
HCV recurrence develop cirrhosis within 5/7 years,
resulting in reduced long-term survival rates [95,96].
In contrast to whole DDLT, survival outcomes and
effects of recurrence following adult LDLT for HCV
are not yet defined. Preliminary reports showed an
earlier severe recurrence within the first year after
transplantation, with higher incidence of cholestatic
hepatitis [97]. In this case, the advantages of early
transplantation may be offset by the risk of graft
failure imposed by early recurrent disease. Never-
theless, an emerging strategy for preventing recurrent
HCV infection is pre-transplant treatment to achieve
viral eradication (especially in patients with HCC and
compensated cirrhosis with a good viral profile: non-
genotype 1 or genotype 1 with low viral load) followed
by timed LDLT [98,99]. If such strategies become
successful, LDLT may exhibit an advantage over
DDLT.
The extension of the indications for LDLT should
be drawn carefully and individually based on both
patient and donor safety. Nevertheless, LDLT opens
new perspectives for patients with advanced HCC,
decompensated end-stage liver disease, and HCV
cirrhosis.
Ethical considerations
LDLT has always been accompanied by ethical
concerns, mainly related to the risk imposed on the
donor [100,101]. Over the past decade, it has been
proven that LDLT significantly increases the donor
pool and that the outcome is equal or even superior to
DDLT. In this sense, the risk benefit/ratio for the
recipient is clearly in favor of LDLT [102]. Applying
the principle of justice to LDLT is also complex,
and nobody knows whether a procedure that violates
the principle ‘above all, do no harm’ can be justified.
Further, ongoing ethical discussions are concerned
with questions such as who should receive a living
donor transplant. While some argue that stable
patients with chronic liver disease, before hepatic
decompensation, benefit the most from LDLT,
others maintain that very ill patients are precisely
the ones who should be offered LDLT [103,104]. An
extension of this argument is concerned with patients
who cannot currently be placed on the waiting list due
to advanced cancer, but in which LDLT offers the
only effective option. Disagreement still exists about
patients with acute hepatic failure, even though
several reports have shown that patients with acute
hepatic failure can be well served by LDLT
[103,105].
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However, who should donate then? LDLT is
guided by two main principles: (1) donor morbidity
and mortality must be kept to a minimum; and (2)
graft and recipient survival should be as high as in full
size LDLT. The exact risk to the living donor is not
known. The evidence from several surveys and sub-
jective assessments indicates that donor mortality is
somewhere between 0.2 and 1% and morbidity as
high as 60% [106]. Trotter reported that a complete
recovery required more than 3 months in 75% of all
donors [107]. Despite all this, recent studies have
shown a significant benefit for the donor. Liver donors
reported satisfaction and increased self-esteem. In a
study by Karliova et al., 92% of all donors would
decide to donate again [108]. A high degree of
preoperative information enabled the donors to have
a realistic view of the operation and its potential
complications and explained the overall positive retro-
spective rating.
Clearly, donor safety is paramount in LDLT, and
the risks and benefits to the donors will undoubtedly
be debated by ethicists.
Conclusions
In the last decades, LDLT has emerged as a clinically
safe addition to DDLT. The widespread adoption of
LDLT has the potential to decrease waiting list
mortality. The advantages of LDLT are obvious: (1)
transplantation can be performed on an elective basis
before serious decompensation of the recipient; and
(2) complications due to organ preservation are
minimized or completely absent, and grafts are
generally in excellent condition. Although the benefits
are enormous, the physical and psychological sacrifice
of the donors is immense, and the expectations for a
good outcome for themselves, as well as for the
recipients, are high. Donor safety has an absolute
priority, and only the assurance of a low morbidity
and zero mortality can justify this procedure.
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